Toxicity and efficacy of intrathecal liposomal cytarabine in children with leukemia/lymphoma relapsing in the central nervous system: a retrospective multicenter study

References

• Pui C-H, Thiel E. Central nervous system disease in haematological malignancies:historical perspective and practical applications. Semin Oncol 2009;36:S2–S16.
   PubMed Web of Science ®Google Scholar
• Barredo JC, Devidas M, Lauer SJ, et al. Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a pediatric oncology group study. J Clin Oncol 2006;24:3142–3149.
   PubMed Web of Science ®Google Scholar
• Johnston DL, Alonzo TA, Gerbing RB, et al. Risk factors and therapy for isolated central nervous system relapse of pediatric acute myeloid leukemia. J Clin Oncol 2005;23:9172–9178.
   PubMed Web of Science ®Google Scholar
• Murry DJ, Blaney SM. Clinical pharmacology of endocapsulated sustained-release cytarabine. Ann Pharmacother 2000;34:1173–1178.
   PubMed Web of Science ®Google Scholar
• Bomgaars L, Geyer JR, Franklin J, et al. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. J Clin Oncol 2004;22:3916–3921.
   PubMed Web of Science ®Google Scholar
• Benesch M, Sovinz P, Krammer B, et al. Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adult with refractory neoplastic meningitis. J Pediatr Hematol Oncol 2007;26: 222–226.
   Web of Science ®Google Scholar
• Parasole R, Menna G, Marra N, et al. Efficacy and safety of intrathecal liposomal cytarabine for the treatment of meningeal relapse in acute lymphoblastic leukemia:experience of two pediatric institutions. Leuk Lymphoma 2008;49:1553–1559.
   PubMed Web of Science ®Google Scholar
• Jabbour E, O’Brien S, Kantarjian H, et al. Neurological complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphoblastic leukemia. Blood 2007;109:3214–3218.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Glantz MJ. Neurological complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphoblastic leukemia. Blood 2007;110:1698.
   PubMed Web of Science ®Google Scholar
• Pui C-H. Toward optimal use of intrathecal liposomal cytarabine. Leuk Lymphoma 2007;48:1672–1673.
   PubMed Web of Science ®Google Scholar
• McClune B, Buadi FK, Aslam N, et al. Intrathecal liposomal cytarabine for prevention of meningeal disease in patients with acute lymphoblastic leukemia and high-grade lymphoma. Leuk Lymphoma 2007;48:1849–1851.
   PubMed Web of Science ®Google Scholar
• Gökbuget N, Hartog C-M, Bassan R, et al.; the German Multicenter Study Group for Adult ALL and the European Working Group for Adult ALL. Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma. Haematologica 2011;96:238–244.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf
   Google Scholar
• Kaplan EL, Meier P. Non parametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457–481.
   Web of Science ®Google Scholar
• Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996;17:343–346.
   PubMedGoogle Scholar
• Vezmar S, Becker A, Bone U, et al. Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy 2003;49:92–104.
   PubMed Web of Science ®Google Scholar
• Parasole R, Petruzziello F, Menna G, et al. Central nervous system complications during treatment of acute lymphoblastic leukemia in a single pediatric institution. Leuk Lymphoma 2010;51:1063–1071.
   PubMed Web of Science ®Google Scholar
• Bhojwani D, Pui C-H. Intrathecal liposomal cytarabine: more friend than foe? Leuk Lymphoma 2008;49:1427–1430.
   PubMed Web of Science ®Google Scholar
• Peyrl A, Sauermann R, Traunmueller F, et al. Pharmacokinetics and safety of intrathecal liposomal cytarabine in children aged < 3 years. Clin Pharmacokinet 2009;48:265–271.
   PubMed Web of Science ®Google Scholar
• Morris EB, Laningham FH, Sandlund JT, et al. Posterior reversible encephalopathy syndrome in children with cancer. Pediatr Blood Cancer 2007;48:152–159.
   PubMed Web of Science ®Google Scholar
• Eapen M, Zhang MJ, Devidas M, et al.; Children's Oncology Group; Center for International Blood and Marrow Transplant Research. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with acute lymphoblastic leukemia in a second remission after isolated central nervous system relapse: a cooperative study of Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. Leukemia 2008;22:281–286.
   PubMed Web of Science ®Google Scholar
• van den Berg H, de Groot-Kruseman HA, Damen-Korbijn CM, et al. Outcome after first relapse in children with acute lymphoblastic leukemia: a report based on the Dutch Childhood Oncology Group (DCOG) relapse all 98 protocol. Pediatr Blood Cancer 2011;57:210–216.
   PubMed Web of Science ®Google Scholar
• Mastronuzzi A, Del Bufalo F, Iacono A, et al. Intrathecal liposomal cytarabine and leptomeningeal medulloblastoma relapse: a valuable therapeutic option. Anticancer Res 2013;33:3515–3518.
   PubMed Web of Science ®Google Scholar
• Goldsby RE, Liu Q, Nathan PC, et al. Late-Occurring Neurologic Sequelae in Adult Survivors of Childhood Acute Lymphoblastic Leukemia:A Report From the Childhood Cancer Survivor Study. J Clin Oncol 2010;28:324–331.
   PubMed Web of Science ®Google Scholar
• Renard M, Suciu S, Bertrand Y, et al.; EORTC Children Leukaemia Group (CLG). Second neoplasm in children treated in EORTC 58881 trial for acute lymphoblastic malignancies: low incidence of CNS tumours. Pediatr Blood Cancer 2011;57:119–125.
   PubMed Web of Science ®Google Scholar